COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice

Scand J Gastroenterol. 2005 Aug;40(8):903-13. doi: 10.1080/00365520510015827.

Abstract

Objective: Neutrophil activation followed by free radical production is a feature that is common to the various forms of gastric injury. However, the roles of cyclooxygenase (COX)-1 and -2 in neutrophil activation have yet to be clarified in the gastric mucosa. We examined the roles of both COX-1 and COX-2 in neutrophil activation and free radical production in ischemia-reperfusion (IR) injury in the gastric mucosa of mice.

Material and methods: Ischemia was induced by clamping the celiac artery for 30 min, then removing the clamp for 90 min. SC-560, a selective COX-1 inhibitor; NS-398, a selective COX-2 inhibitor; or rebamipide, a mucoprotective agent, was administered to mice 60 min before ischemia. Gastric damage was evaluated histologically and by measuring myeloperoxidase (MPO) activity. Expressions of COX protein and intercellular adhesion molecule (ICAM)-1 were evaluated by Western blot analysis and ELISA, respectively. Effects of these drugs on thiobarbituric acid reactive substances (TBARS) and gastric blood flow were also evaluated.

Results: COX-2 expression was induced in gastric mucosa 60 min after reperfusion, whereas COX-1 expression remained unaltered. Localization of COX-1 and ICAM-1 in IR-injured mucosa was observed mainly in endothelial cells, while COX-2 expression was detected in mesenchymal cells such as mononuclear cells, spindle-like cells and endothelial cells. SC-560 significantly decreased gastric blood flow at the reperfusion point and reduced gastric mucosal injury in IR mice. Furthermore, SC-560 pretreatment significantly reduced MPO activity, TBARS levels and ICAM-1 expression. In contrast, NS-398 significantly increased ICAM-1 expression, MPO activity and TBARS levels, and aggravated gastric damage in IR mice. Rebamipide pretreatment reduced both COX-2 expression and IR injury.

Conclusions: In IR mice, COX-2 protects the gastric mucosa by down-regulating ICAM-1 expression, whereas COX-1 is involved in up-regulating reperfusion flow, thereby aggravating the mucosa.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Animals
  • Blotting, Western
  • Celiac Artery / surgery
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / therapeutic use
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gastric Mucosa / blood supply*
  • Gastric Mucosa / enzymology
  • Intercellular Adhesion Molecule-1 / metabolism
  • Laser-Doppler Flowmetry
  • Ligation
  • Membrane Proteins
  • Mice
  • Mice, Inbred ICR
  • Nitrobenzenes / therapeutic use
  • Peroxidase / metabolism
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • Pyrazoles / therapeutic use
  • Quinolones / therapeutic use
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology
  • Reperfusion Injury / enzymology*
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / prevention & control
  • Sulfonamides / therapeutic use
  • Thiobarbituric Acid Reactive Substances / metabolism

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Membrane Proteins
  • Nitrobenzenes
  • Pyrazoles
  • Quinolones
  • SC 560
  • Sulfonamides
  • Thiobarbituric Acid Reactive Substances
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • Intercellular Adhesion Molecule-1
  • Peroxidase
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Ptgs1 protein, mouse
  • rebamipide
  • Alanine